WuXi AppTec Aiming To Relist Biologics Unit In Hong Kong IPO
This article was originally published in PharmAsia News
WuXi AppTec is planning to spin out its biologics CRO/CMO unit in a Hong Kong IPO that is likely to raise at least $367m, sources have confirmed. The new funding would provide the fast-growing Wuxi Biologics subsidiary with the freedom and resources to make its own pipeline portfolio decisions.
Register for our free email digests: